


Stabilis



Cyclophosphamide



Nomes comerciais nos diversos países

Alkyloxan	Egipto, Malásia
Celomide	Índia
Ciclofosfamida	Argentina, Chilli, Romènia
Cicloxal	Espanha
Cryofaxol	México
Cycloblastin	Austrália
Cycloblastine	Países Baixos
Cyclophosphamid	Alemanha, Dinamarca
Cyclophosphamide	Arábia Saudita, Estados Unidos de América, Gran-bretanha, nova Zelândia
Cyclostin	Alemanha
Cycloxan	Malásia
Cycram	Egipto
Cytoxan	Canadá, Estados Unidos de América, Hungria
Eldamide	Índia
Endoxan	Alemanha, Arábia Saudita, Austrália, Áustria, Bélgica, Chilli, Colômbia, Croácia, Emirados Árabes Unidos, Equador, Eslovénia, França, Grécia, Hungria, Índia, Irã, Itália, Luxemburgo, Marrocos, nova Zelândia, Países Baixos, Polónia, Portugal, Suíça, Tailândia, Tunísia, Turquia, Venezuela
Endoxana	Gran-bretanha, Irlanda
Formitex	Colômbia, México
Genoxal	Espanha
Genuxal	Brasil
Hidrofosmin	México
Ledoxan	Colômbia
Ledoxina	Colômbia, México
Neophos	Egipto
Neosar	Estados Unidos de América
Procytox	Canadá
Sendoxan	Dinamarca, Finlândia, Islândia, Noruega, Suécia
Syklofosamid	Finlândia, Turquia



Estabilidade em soluções simples

		20 mg/ml	24-27°C		4			1728
		20 mg/ml	4°C		7			172
		20 mg/ml	5°C		14			1728
		0,4 mg/ml	2-8°C		14			1728
		0,4 mg/ml	21-25°C		6			1728
		1 mg/ml	25°C		7			172
		1 mg/ml	4°C		7			172
		1 mg/ml	25°C		7			172
		1 mg/ml	4°C		7			172
		20 mg/ml	4°C		7			172
		1 mg/ml	25°C		7			172
		1 mg/ml	4°C		7			172
		10 mg/ml	4°C		30			40
		1 mg/ml	25°C		2			172
		1 mg/ml	4°C		7			172
		10 mg/ml	4°C		30			40
		0,24 & 6,4 mg/ml	25°C		7			1520
		0,24 & 6,4 mg/ml	25°C		7			1520
		2 mg/ml	2-8°C		5			4989
		2 mg/ml	25°C		60			4989
		20 mg/ml	2-8°C		6			4989
		20 mg/ml	25°C		24			4989
		2 mg/ml	2-8°C		6			4989
		2 mg/ml	25°C		60			4989
		20 mg/ml	2-8°C		3			4989
		20 mg/ml	25°C		24			4989
		20 mg/ml	2-8°C		6			4865
		20 mg/ml	25°C		24			4865
		2 mg/ml	2-8°C		36			4865
		2 mg/ml	25°C		24			4865

?		2 mg/ml	2-8°C	?	6			4865
?		2 mg/ml	25°C	?	24			4865



Estabilidade em misturas

								
		1 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
		10 mg/ml	25°C		Palonosetron hydrochloride : 50 µg/ml	4		2016
		1 mg/ml	20°C		Mesna : 0,2 & 1 mg/ml	24		2104
		5 mg/ml	20°C		Mesna : 1 mg/ml	24		2104
		10 mg/ml	20°C		Mesna : 2 & 10 mg/ml	24		2104
		0,3 mg/ml	23°C-25°C		Ondansetron hydrochloride : 0,05 mg/ml	4		50
		2 mg/ml	23°C-25°C		Ondansetron hydrochloride : 0,4 mg/ml	4		50
		0,3 mg/ml	4°C		Ondansetron hydrochloride : 0,05 mg/ml	8		50
		2 mg/ml	4°C		Ondansetron hydrochloride : 0,4 mg/ml	8		50
		0,3 mg/ml	23°C-25°C		Ondansetron hydrochloride : 0,05 mg/ml	4		50
		2 mg/ml	23°C-25°C		Ondansetron hydrochloride : 0,4 mg/ml	4		50
		0,3 mg/ml	4°C		Ondansetron hydrochloride : 0,05 mg/ml	8		50
		2 mg/ml	4°C		Ondansetron hydrochloride : 0,4 mg/ml	8		50
		1,8 mg/ml	22°C		Mesna : 0,54 mg/ml	6		1833
		10,8 mg/ml	22°C		Mesna : 3,2 mg/ml	24		1833
		10,8 mg/ml	4°C	?	Mesna : 3,2 mg/ml	48		1833
		1,8 mg/ml	4°C	?	Mesna : 0,54 mg/ml	48		1833
		10 mg/ml	20°C-23°C		Topotecan : 0,028 mg/ml	4		1026
		10 mg/ml	20°C-23°C		Topotecan : 0,028 mg/ml	4		1026



Factores que afectam a sua estabilidade

					172
	>70°C				170



Compatibilidade

				
		Cyclophosphamide : 20 mg/ml		150
		Cyclophosphamide		4865
		Cyclophosphamide		4865
		Cyclophosphamide : 10 mg/ml		301
		Cyclophosphamide : 10 mg/ml		1415
		Cyclophosphamide		4989
		Cyclophosphamide : 10 mg/ml Allopurinol sodium : 3 mg/ml		307
		Cyclophosphamide : 10 mg/ml Amifostine : 10 mg/ml		3
		Cyclophosphamide : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Cyclophosphamide		4989
		Cyclophosphamide : 10 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Cyclophosphamide : 10 mg/ml Aztreonam : 40 mg/ml		99
		Cyclophosphamide : 10 mg/ml Cladribine : 0.5 mg/ml		1496
		Cyclophosphamide : 10 mg/ml Cladribine : 0.015 mg/ml		1496
		Cyclophosphamide : 10 mg/ml Doripenem : 5 mg/ml		2262
		Cyclophosphamide : 10 mg/ml Doripenem : 5 mg/ml		2262
		Cyclophosphamide : 10 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Cyclophosphamide : 10 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Cyclophosphamide : 10 mg/ml Filgrastim : 30 µg/ml		244
		Cyclophosphamide : 10 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Cyclophosphamide : 20 mg/ml Gallium nitrate : 1 mg/ml		91
		Cyclophosphamide : 10 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Cyclophosphamide : 2 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Cyclophosphamide : 1 mg/ml Hydroxyzine dihydrochloride : 0.5 mg/ml		331
		Cyclophosphamide : 4 mg/ml Idarubicin hydrochloride : 1 mg/ml		491

		Cyclophosphamide : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Cyclophosphamide : 10 mg/ml Linezolid : 2 mg/ml		1925
		Cyclophosphamide : 10 mg/ml Melfalan : 0.1 mg/ml		169
		Cyclophosphamide : 1.8 mg/ml Mesna : 0.54 mg/ml		1833
		Cyclophosphamide : 10.8 mg/ml Mesna : 3.2 mg/ml		1833
		Cyclophosphamide : 1 >> 10 mg/ml Mesna : 0.2 >> 10 mg/ml		2104
		Cyclophosphamide : 20 mg/ml Methotrexate sodium : 30 mg/ml		150
		Cyclophosphamide Mitomycin		4471
		Cyclophosphamide Mitomycin		3128
		Cyclophosphamide : 2 mg/ml Ondansetron hydrochloride : 0,4 mg/ml		50
		Cyclophosphamide : 0,3 mg/ml Ondansetron hydrochloride : 0,05 mg/ml		50
		Cyclophosphamide : 20 mg/ml Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml		3574
		Cyclophosphamide : 0,3 mg/ml Ondansetron hydrochloride : 0,05 mg/ml		50
		Cyclophosphamide : 2 mg/ml Ondansetron hydrochloride : 0,4 mg/ml		50
		Cyclophosphamide : 10 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Cyclophosphamide : 10 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Cyclophosphamide : 10 mg/ml Paclitaxel : 1.2 mg/ml		85
		Cyclophosphamide : 10 mg/ml Palonosetron hydrochloride : 50 µg/ml		2016
		Cyclophosphamide : 10 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Cyclophosphamide : 10 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Cyclophosphamide : 10 mg/ml Propofol : 10 mg/ml		300
		Cyclophosphamide : 4 mg/ml Propofol		660
		Cyclophosphamide : 10 mg/ml Sargramostim : 10 µg/ml		335
		Cyclophosphamide : 20 mg/ml Sodium bicarbonate : 14 mg/ml		150
		Cyclophosphamide : 10 mg/ml Teniposide : 0.1 mg/ml		905
		Cyclophosphamide : 10 mg/ml Thiotepa : 1 mg/ml		249

	Cyclophosphamide : 20 mg/ml Topotecan : 0.056 mg/ml		1026
	Cyclophosphamide : 20 mg/ml Topotecan : 0.056 mg/ml		1026
	Cyclophosphamide : 10 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Método de administração



Bibliografia

	tipo	publicação
3	jornal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
40	jornal	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
50	jornal	Fleming RA, Olsen DJ, Savage PD, Fox JL. Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions. Am J Health-Syst Pharm 1995 ; 52: 514-516.
57	jornal	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	jornal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	jornal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	jornal	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	jornal	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	jornal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	jornal	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.

169	jornal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
170	jornal	Brooke D, Scott JA, Bequette RJ. Effect of briefly heating cyclophosphamide solutions. Am J Hosp Pharm 1975 ; 62: 44-45.
172	jornal	Beijnen JH, van Gijn R, Challa EE, Kaijser GP, Underberg WJM. Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids. J Parenter Sci Technol 1992 ; 46: 111-116.
244	jornal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	jornal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	jornal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	jornal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	jornal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	jornal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	jornal	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplastic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	jornal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	jornal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
491	jornal	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	jornal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
660	jornal	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
905	jornal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.


921	jornal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	jornal	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410	jornal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	jornal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	jornal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	jornal	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Laboratório	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	jornal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	jornal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1728	jornal	Mittner A, Vincze Z, Jemnitz. Stability of cyclophosphamide containing infusions. Pharmazie 1999 ; 54: 224-225.
1833	jornal	Menard C, Bourguignon C, Schlatter J, Vermerie N. Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags. Ann Pharmacotherapy 2003 ; 37, 12: 1789-1792.
1925	jornal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	jornal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	jornal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2016	jornal	Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2104	jornal	Iriarte Izura MA, Gozalo garcia MJ, Marcotegui Ros F, Nagore Indurain C, Urdaniz Baztan AO. Estudio de la estabilidad de mezclas ciclofosfamida/mesna e ifosfamida/mesna en soluciones intravenosas de gran volumen. Farm Hosp 2000 ; 24: 145-150
2262	jornal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmore T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.

3128	Laboratório	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3574	Laboratório	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
4471	Laboratório	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4865	Laboratório	Cyclophosphamide REDDY PHARMA 2000 mg/4 ML, solution à diluer pour solution injectable/perfusion. - Résumé des caractéristiques du produit. Dr REDDY laboratoire 2024
4989	Laboratório	Extended dilution stability study report of cyclophosphamide concentrate for solution for infusion at room temperature and refrigerated condition (2-8°C) - Personal communication - July 2025 Dr REDDY 2023

Stabilis



Cyclophosphamide



Estabilidade de preparações farmacêuticas

		24 mg @=? (Baxter)	NaCl 0.9% 1.2 ml xarope simples 1.2 ml	4°C		56		3096
		24 mg @=? (Baxter)	NaCl 0.9% 1.2 ml OraPlus® 1.2 ml	4°C		56		3096




Bibliografia

	tipo	publicação
3096	jornal	Kennedy R, Groepper D, Tagen M, Christensen R, Navid F, Gajjar A, Stewart CF. Stability of Cyclophosphamide in Extemporaneous Oral Suspensions. Ann Pharmacotherapy 2010 ;44:295-301.

Stabilis



Cyclophosphamide



Estabilidade de preparações farmacêuticas

?		10 mg Endoxan®	lactose >>	?	?	70		2000



Bibliografia

	tipo	publicação
2000	jornal	Bouligand J, Storme T, Laville I, Mercier L, Oberlin O, Vassal J, Bourget Ph, Paci A. Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products. J Pharm Biomed Anal 2005 ; 38: 180-185.



Dicionário

	droga contra o câncer		injetável
	Nomes comerciais nos diversos países		Estabilidade em soluções simples
	Embalagem		Molécula
	concentração		temperatura
	conservação		Duração da estabilidade
	biossimilar		dados conflitantes
	Bibliografia		vidro
	Agua para injectaveis		no especificado
	dia		ao abrigo da luz
	cloreto de sódio 0,9%		Glucose 5%
	Cloreto de polivinilo		Polietileno
	Poliolefina		luz
	hora		no especificado
	cloreto de sódio 0,45%		Estabilidade em misturas
	Solvente		molécula
	Factores que afectam a sua estabilidade		Aumento
	Provoca		Degradação
	Compatibilidade		Compatível
	NaHCO3		NaCl 0,45% Glucose 5%
	Nutrição parenterica (mistura binária)		Nutrição parenteral (com lípidos)
	Turvação imediata		Incompatível
	NaCl 0,9% + bacteriostático		Precipitação após 4 horas
	nenhum		Incompatibilidade não especificada
	Instabilidade química		Instabilidade da emulsão após 24 horas
	Método de administração		intravenoso
	perfusão intravenosa		Perfusão continua
	intramuscular		Intra-arterial
	intrapleural		intraperitoneal
	Bibliografia		Solução Oral
	Estabilidade de preparações farmacêuticas		Origine

	excipiente		seringa
	frasco de medicamento para injeção		Cápsula
	cápsulas		Dicionário